1445860-68-3

Basic information

• Product Name: 4-(3'-chloro-4'-fluorophenylamino)-6-[3-(2-oxa-6-azaspiro[3.4]octane-6-yl)propoxy]-7-methoxyquinazoline
• CAS NO: 1445860-68-3
• Molecular Weight: 472.947
• Mol File: 1445860-68-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-(3'-chloro-4'-fluorophenylamino)-6-[3-(2-oxa-6-azaspiro[3.4]octane-6-yl)propoxy]-7-methoxyquinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3'-chloro-4'-fluorophenylamino)-6-[3-(2-oxa-6-azaspiro[3.4]octane-6-yl)propoxy]-7-methoxyquinazoline(1445860-68-3)
• EPA Substance Registry System: 4-(3'-chloro-4'-fluorophenylamino)-6-[3-(2-oxa-6-azaspiro[3.4]octane-6-yl)propoxy]-7-methoxyquinazoline(1445860-68-3)

Safety Data

• Hazardous Substances Data: 1445860-68-3(Hazardous Substances Data)

Upstream product

• 220290-68-6 2-oxa-6-azaspiro[3.4]octane hemioxalate 
• 912556-91-3 6-(3-chloropropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-ylamine 
• 692059-41-9 6-(3-chloropropoxy)-4-chloro-7-methoxyquinazoline 
• 574738-93-5 6-(3-chloropropoxy)-7-methoxyquinazolin-4-ol 
• 380844-26-8 methyl 5-(3-chloropropoxy)-2-amino-4-methoxybenzoate 
• 380844-24-6 methyl 5-(3-chloropropoxy)-4-methoxy-2-nitrobenzoate 
• 380844-22-4 methyl 3-(3-chloropropoxy)-4-methoxybenzoate 
• 929683-54-5 3-(3-chloropropoxy)-4-methoxybenzaldehyde 
• 621-59-0 isovanillin 

Relevant articles and documents

Heterocycle Amido Alkyloxy Substituted Quinazoline Derivative and Use Thereof

Heterocycle amino alkyloxy substituted quinazoline derivatives as represented by the structural Formula (I) and pharmaceutically acceptable salts thereof, capable of inhibiting the activity of receptor tyrosine kinase EGFR, and being used to treat cancers related to the expression of the receptor tyrosine kinase of the ErbB family are provided.

Four-membered heterocycles-containing 4-anilino-quinazoline derivatives as epidermal growth factor receptor (EGFR) kinase inhibitors

We report herein the design and synthesis of novel azaspirocycle or azetidine substituted 4-anilinoquinazoline derivatives. The EGFR inhibitory activities and in vitro antitumor potency of these newly synthesized compounds against two lung cancer cell lines HCC827 and A549 were evaluated. Most of the target compounds possess good inhibitory potency. In particular, compounds 21g with 2-oxa-6-azaspiro[3.4]octane substituent was found to possess higher EGFR inhibitory activities and similar antitumor potency comparing to the lead compound gefitinib with improved water solubility.